News & Updates
Filter by Specialty:
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
25 Jul 2023Study: Older COVID-19 patients with epilepsy, multimorbidity highly vulnerable
Factors such as older age (>65 years), ventilator use, and higher comorbidity all contribute to increased mortality risk with COVID-19 among patients with epilepsy, as reported in a study.
Study: Older COVID-19 patients with epilepsy, multimorbidity highly vulnerable
24 Jul 2023Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.